| Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 21256048 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tadalafil 40 mg orally once daily, was shown to be well-tolerated and efficacious for pulmonary arterial hypertension in a 16-week, double-blind, placebo (PBO)-controlled trial. Inclusion criteria included the option for background bosentan. Analyses of tadalafil in treatment-naive patients and as add-on to bosentan were pre-specified. Objectives were to provide safety and efficacy data for both groups. METHODS: Groups analyzed included: treatment-naive + PBO; treatment-naive + tadalafil; background bosentan + PBO; and background bosentan + tadalafil. Patients randomized to tadalafil or PBO (N = 405) were analyzed by bosentan use (yes = 216, no = 189). Treatment differences in 6-minute walk distance (6MWD, PBO-adjusted), functional class (FC), clinical worsening (CW) and adverse events were assessed. Hazard ratios (HRs) with 95% confidence intervals (CIs) are presented for FC and CW. RESULTS: At Week 16, PBO-adjusted 6MWD increases were 44 m (CI: 20 to 69 m; n = 37) for tadalafil 40 mg in treatment-naive patients and 23 m (CI: -2 to 48 m; n = 42) for tadalafil 40 mg add-on to bosentan. The 6MWD for treatment-naive and background bosentan PBO patients decreased by 3 m and increased by 19 m, respectively, at Week 16 compared with baseline. Two (5%) treatment-naive patients had CW with tadalafil 40 mg vs 8 (22%) with PBO (HR = 3.3, CI: 1.1 to 10.0). Two (5%) background bosentan patients had CW with tadalafil 40 mg add-on vs 5 (11%) for PBO add-on (HR = 1.9, CI: 0.4 to 10.2). Adverse events for tadalafil monotherapy and as add-on were similar. CONCLUSION: Tadalafil 40 mg was well-tolerated and provided clinical benefit in patients as monotherapy. It was also well-tolerated when added to background bosentan, but data are insufficient to conclude additional benefit. |
| | |
Authors:
|
Robyn J Barst; Ronald J Oudiz; Anthony Beardsworth; Bruce H Brundage; Gerald Simonneau; Hossein A Ghofrani; David P Sundin; Nazzareno Galiè; |
Related Documents
:
|
21494068 - Bilateral subthalamic nucleus stimulation in the treatment of neurodegeneration with br... 20658448 - Utility of diffusion-weighted mri for assessing liver fibrosis in patients with chronic... 21297318 - Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 m... 21509668 - Effects of external application of chinese medicine on diabetic ulcers and the expressi... 16120118 - Fluconazole and/or hexetidine for management of oral candidiasis associated with dentur... 7376838 - Anterior displacement of the tibial tuberosity in the treatment of chondromalacia patel... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2011-01-21 |
Journal Detail:
|
Title: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Volume: 30 ISSN: 1557-3117 ISO Abbreviation: J. Heart Lung Transplant. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-05-10 Completed Date: 2011-08-26 Revised Date: 2013-06-18 |
Medline Journal Info:
|
Nlm Unique ID: 9102703 Medline TA: J Heart Lung Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 632-43 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Pediatrics and Medicine, Columbia University, New York, New York, USA. robyn.barst@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antihypertensive Agents / adverse effects, therapeutic use* Carbolines / adverse effects, therapeutic use* Double-Blind Method Drug Therapy, Combination Female Humans Hypertension, Pulmonary / drug therapy* Male Middle Aged Sulfonamides / adverse effects, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Carbolines; 0/Sulfonamides; 0/tadalafil; Q326023R30/bosentan |
| Investigator | |
Investigator/Affiliation:
|
N Galie / ; Z Safdar / ; S Shapiro / ; R J White / ; R J Barst / ; E Rosenzweig / ; R Girgis / ; F Grimminger / ; A Ghofrani / ; W Seeger / ; J Feldman / ; G Simonneau / ; J Klinger / ; V Cottin / ; J Granton / ; N Nakanishi / ; G Staehler / ; S Mehta / ; G Coghlan / ; D Ostrow / ; D Badesch / ; J Behr / ; L Bruch / ; H Farber / ; T Mubarak / ; C Lawrence / ; C Markin / ; O Minai / ; G Saydain / ; M Widmer / ; B Degano / ; S Fazio / ; M Gomberg-Maitland / ; D Langleben / ; J Meyer / ; J Michaelson / ; E Michelakis / ; R Naeije / ; A Peacock / ; B Rayburn / ; M Chakinala / ; St Louis / ; T DeMarco / ; F Fedele / ; R Frantz / ; M A Gomez-Sanchez / ; D Helmersen / ; P Hernandez / ; A Hurewitz / ; A Waxman / ; D Baratz / ; C Campana / ; E Hachulla / ; N Hill / ; S Knoper / ; K Kusano / ; M Mathier / ; S Murali / ; S Ogawa / ; J Pepke-Zaba / ; J Barbera / ; R Oudiz / ; J Beckman / ; D Camanga / ; Z Bshouty / ; M Delcroix / ; R Ewert / ; J Gossage / ; F Grimminger / ; H Matsubara / ; O Miera / ; M Mizoguchi / ; M Pfeifer / ; M Reynaud-Gaubert / ; H Watanabe / ; D Zwicke / ; P Corris / ; G Elliott / ; H Endo / ; P Fairman / ; S Gaine / ; D Kiely / ; Y Kihara / ; H Kuraishi / ; P Morales-Martin / ; J Suzuki / ; Y Takeda / ; T Ziedalski / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vastus lateralis oxygenation dynamics during maximal fatiguing concentric and eccentric isokinetic m...
Next Document: The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium ...